CSL and Vitaeris Inc have announced they have entered into a strategic collaboration and purchase option agreement to expedite the development of clazakizumab, an anti-IL6 MAB, formerly ALD518, as a therapeutic option for solid organ transplant rejection.The above snippet is the first part of an article sent to subscribers in Pharmacy Daily's issue from 06 Dec 17 To see the full story, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 Dec 17
THE Consumers Health Forum of Australia (CHF) is seeking a voice at the table when negotiations begin for the next Community Pharmacy Agreement (CPA) following confirmation by Health Minister Greg Hunt that the Pharmaceutical Society of Australia (PSA) will also be involved (PD yesterday).
CONSIDERED one of Australia’s most urgent public health crises, opioid-related harm is the central theme in the latest issue of the Society of Hospital Pharmacists of Australia (SHPA)’s flagship organ the Journal of Pharmacy Practice and Research (JPPR).
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.